Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chronos Therapeutics
Oxford, England, United Kingdomchronostherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chronos Therapeutics is developing small molecule therapeutics for degenerative and behavioral diseases of the brain and nervous system. Its lead compound RDC5 targets ALS. The company has acquired several CNS programs from Shire targeting fatigue in MS and other neurodegenerative/behavioral conditions. Most pipeline assets are in preclinical or discovery stages.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Shire plc—strategic equity investor following asset acquisition deal for CNS development programs.
Beyond the preview
Go deeper on Chronos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chronos Therapeutics.